Hindawi Journal of Ophthalmology Volume 2017, Article ID 5192924, 6 pages https://doi.org/10.1155/2017/5192924

# Research Article

# Effect of Topically Administered Chitosan-N-acetylcysteine on Corneal Wound Healing in a Rabbit Model

Corinna Fischak, <sup>1,2</sup> Robert Klaus, <sup>1,2</sup> René M. Werkmeister, <sup>1,2</sup> Christine Hohenadl, <sup>3</sup> Martin Prinz, <sup>3</sup> Leopold Schmetterer, <sup>1,2,4,5</sup> and Gerhard Garhöfer <sup>6</sup>

Correspondence should be addressed to Gerhard Garhöfer; gerhard.garhoefer@meduniwien.ac.at

Received 27 February 2017; Revised 28 April 2017; Accepted 10 May 2017; Published 12 June 2017

Academic Editor: Taras Ardan

Copyright © 2017 Corinna Fischak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The present study was performed to investigate the effect of topically administered chitosan-N-acetylcysteine (C-NAC) on corneal wound healing in a rabbit model. Methods. A total of 20 New Zealand White rabbits were included in the randomized, masked, placebo-controlled experiment. A monocular epithelial debridement was induced by manual scraping under general anesthesia. Animals were randomized to receive either C-NAC two times daily or placebo. Monitoring of corneal wound healing was performed with ultra-high-resolution optical coherence tomography (OCT) and epithelial fluorescein staining. Measurements were done immediately after and up to 72 hours after wound induction. Results. No difference in wound size was found immediately after surgical debridement between the C-NAC group and the placebo group. Wound healing was significantly faster in the C-NAC group compared to the placebo group (p < 0.01 for both methods). A good correlation was found between the OCT technique and the epithelial fluorescein staining in terms of wound size (r = 0.94). Conclusions. Administration of C-NAC containing eye drops twice daily leads to a faster corneal wound healing in a rabbit model of corneal debridement as compared to placebo. Ultra-high-resolution OCT is considered a noninvasive, dye-free alternative to conventional fluorescein staining in assessing corneal wound healing also in humans.

# 1. Background

Normal visual function is strongly dependent on an intact corneal surface [1]. Corneal epithelial defects are associated not only with reduced and/or blurred vision but also with ocular discomfort including pain, tearing, light sensitivity, eye redness, and foreign body sensation [1]. Causes for corneal epithelial defects include not only mechanical injuries, such as ocular surface traumas, ocular inflammatory diseases, and neurotrophic diseases, but also iatrogenic ophthalmic procedures.

To ensure fast wound healing after corneal injuries, the corneal epithelium has the ability to renew itself by a

complex sequence of epithelial cell apoptosis, proliferation, migration, differentiation, and extracellular matrix remodeling [2]. Depending on the cause and the size of the area of the corneal damage, wound healing in humans may take up to 7 days, which corresponds to the reported turnover of the corneal epithelium [3, 4] Current treatment strategies for corneal epithelial defects include treatment with artificial tears and topical lubricants, frequently used in combination with topical antibiotics [5, 6]. Artificial tears and lubricants not only reduce the mechanical stress and therefore ocular discomfort but also dilute inflammatory cytokines, which in turn may be beneficial for corneal wound healing [1, 2, 7–9].

<sup>&</sup>lt;sup>1</sup>Center for Medical Physics and Biomedical Engineering, Medical University Vienna, Vienna, Austria

<sup>&</sup>lt;sup>2</sup>Christian Doppler Laboratory for Ocular Effects of Thiomers, Vienna, Austria

<sup>&</sup>lt;sup>3</sup>Croma Pharma, Korneuburg, Austria

<sup>&</sup>lt;sup>4</sup>Singapore Eye Research Institute, Singapore

<sup>&</sup>lt;sup>5</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

<sup>&</sup>lt;sup>6</sup>Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria

Because of their favorable biological properties, chitosanbased biopolymers have been proposed as scaffold materials for tissue regeneration and wound healing in several organs including the human eye. Among these, chitosan-Nacetylcysteine (C-NAC), a new biopolymer based on thiolated chitosan, has been recently introduced as a compound in topically administered eye drops (Lacrimera®) which received CE marking in Europe. Besides its good lubricant effect, two main advantages make C-NAC an interesting option for the treatment of corneal epithelial effects: First, the mucoadhesive effect of chitosan leads to a long residence time on the ocular surface [10]. Second, the introduction of thiol groups facilitates a chemical interaction of the polymer with ocular surface mucins. Thus, the resulting stabilization of the polymer-mucin network on the ocular surface may be beneficial for ocular wound healing [11, 12].

In the present randomized, masked, parallel group study, the effect of C-NAC on corneal wound healing was investigated in a rabbit model of corneal damage. To assess the corneal wound healing rate, two independent methods were used: ultra-high-resolution optical coherence tomography (OCT) and slit lamp photography of fluorescein-stained ocular epithelium.

#### 2. Methods

2.1. Experimental Paradigm. Female New Zealand White rabbits (Charles River, Germany) weighing 2.3–4.1 kg were included in the experiments. This research followed the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and was approved by the local animal welfare committee. The animals were individually housed in an environmentally controlled room (12:12 h light:dark cycle, temperature 20°C, 60% relative humidity) at the Medical University Vienna, Department of Biomedical Research. Rabbits were fed with a commercial pelleted diet (ssniff K-H), and tap water was supplied ad libitum. Hay was provided as dietary supplementation. Rabbits were acclimated for a minimum of 14 d after arrival before any research manipulations were performed.

Surgical interventions were performed under general anesthesia using intramuscular injection of ketamin and midazolam. In addition, 0.16 ml/kg buprenorphin was administered for analgesia. To avoid pain during the wound healing period, 0.08 ml/kg carprofen was administered every 24 hours.

- 2.1.1. Corneal Wound Healing Model. A circular debridement wound model in rabbits was used to investigate corneal wound healing. For this purpose, a corneal wound of 6 mm in diameter was introduced using a trephine to mark the wound area. Then the corneal epithelium was removed with a dull-bladed knife. Care was taken to avoid damage of deeper corneal layers.
- 2.2. Chitosan-N-acetylcysteine. C-NAC is based on a biopolymeric chitosan backbone, which has been derivatized with thiol groups by the introduction of N-acetylcysteine. C-

NAC eye drops in its final formulation contain 0.1% of the thiolated polymer in a physiologically buffered solution with a mildly acidic pH. The formulation is CE-marked as a medical device under the trade name Lacrimera (Croma Pharma GmbH, Leobendorf, Austria). Safety and efficacy of the product are well described and were shown to be excellent in a recently published controlled, randomized double-masked clinical study [13].

2.2.1. Study Design. The present study was performed in a randomized, controlled, masked, parallel-group design. After induction of the corneal wound, OCT measurements were performed to assess baseline wound size. In case OCT analysis revealed damage of the corneal stroma, the animal was excluded from the trial. Then fluorescein staining was performed, and photographs of the corneal epithelium were taken to assess the wound size. After completion of baseline measurements, either 50  $\mu$ l of placebo (phosphate-buffered saline solution) or C-NAC eye drops were instilled on the ocular surface twice daily. Measurements of corneal wound healing using OCT and fluorescein staining were repeated 12, 24, 36, 48, and 72 hours after corneal wound induction.

#### 2.2.2. Methods

(1) Assessment of Corneal Wound Healing Using Ultra-High-Resolution OCT. Corneal wound healing was assessed with a custom-built ultra-high-resolution OCT system as described previously [14] differing only in the light source used. For technical reasons, the system used in the current study is based on a superluminescent diode (SLD) with a central wavelength of 850 nm and a spectral bandwidth of 165 nm. The theoretical axial resolution of the device is  $1.3 \, \mu \text{m}$  in corneal tissue, while the lateral resolution given by the focusing optics is approximately  $18 \, \mu \text{m}$ . The incident power of the probe beam onto the cornea was set to  $2.5 \, \text{mW}$  for acquisition of the corneal volumes in order to measure the epithelial wound. This value is well below the maximum permissible exposure as specified by ANSI [15] and IEC 60825-1 [16].

For evaluation of corneal wound healing, one OCT volume with a size of  $7.5 \times 7.5 \times 1$  mm (horizontal × vertical × depth) and comprising  $1024 \times 512 \times 1024$  pixels was recorded within 5 seconds. After the first postprocessing steps including rescaling and dispersion compensation, the acquired volumes were resliced in axial direction in order to obtain an en face image of the anterior cornea. The borders of the corneal erosion were segmented using custom software written in LabVIEW (LabVIEW 2013, National Instruments, Austin, TX, USA). To obtain an absolute measure for the wound area, firstly, the scanning range of the OCT system was taken into account. In the second step, the distortion of the en face image due to the curvature of the cornea was corrected.

(2) Assessment of Corneal Wound Healing Using Fluorescein Staining. Fluorescein drops (Minims-Fluorescein Sodium 2.0%; Chauvin Pharmaceuticals Ltd.) were instilled into the

Journal of Ophthalmology 3




FIGURE 1: Area of defect over time after treatment with either placebo or C-NAC. Data are presented individually based on either fluorescein staining of corneal epithelium or optical coherence tomography.

study eye, and photographs were obtained under illumination with cobalt-blue light using a digital camera. To calibrate each image for the calculation of absolute diameters, a ruler was placed near the eye and photographed together with the cornea. The area of corneal abrasion was measured semi-automatically with a custom macro written for ImageJ (National Institutes of Health, Bethesda, MD; available in the public domain at http://rsbweb.nih.gov/ij/). Measurements were corrected separately for each image using a calibration factor based on the photographs of the ruler.

2.2.3. Data Analysis. To detect differences in the time course between the two treatment groups, a repeated measures ANOVA model was applied. To calculate the correlation between the two different measurement techniques, Pearson's correlation analysis was performed. All statistical analyses were carried out using CSS Statistica (Version 6.0, Tulsa, Oklahoma, US).

# 3. Results

A total of 20 animals were included in the experiment. In the placebo group, baseline defect areas were  $24.6 \, \text{mm}^2 \pm 3.1 \, \text{mm}^2$  as measured using OCT and  $31.4 \, \text{mm}^2 \pm 5.9 \, \text{mm}^2$  as assessed by fluorescein staining,

respectively. In the C-NAC group, baseline areas of corneal debridement were  $27.4\,\mathrm{mm}^2\pm5.5\,\mathrm{mm}^2$  as measured with OCT and  $32.8\,\mathrm{mm}^2\pm4.8\,\mathrm{mm}^2$  as assessed with fluorescein staining. No statistical significant difference was observed in baseline corneal wound size between the C-NAC and the placebo group with neither of the techniques (OCT: p=0.2 between groups, fluorescein staining: p=0.6 between groups).

As shown in Figure 1, wound healing over time was faster in the C-NAC group compared to the placebo group. This was statistically significantly both for the OCT-measured defect size (p < 0.01, ANOVA time versus treatment) and for the fluorescein-measured defect size (p < 0.01, ANOVA time versus treatment). As shown in Figure 2, a good correlation was observed between the two measurement techniques in assessing the size of corneal defect (r = 0.94, p < 0.05).

## 4. Discussion

The data of the present study indicate that corneal wound healing in a rabbit model of epithelial damage was significantly improved when C-NAC containing eye drops were applied compared to the placebo treatment. In addition, it appears that high-resolution OCT is a suitable technique for the noninvasive measurement of corneal epithelial




FIGURE 2: Correlation between areas of defect as measured by photography after fluorescein staining or optical coherence tomography.

damage in the rabbit model of corneal debridement. This is in agreement with a recent study in humans where ultrahigh-resolution OCT was used to quantify epithelial defects in keratoconus patients undergoing standard collagen cross-linking [17].

Besides their valuable role in the treatment of dry eye disease, it is known that topical lubricants containing, for example, hydrating polymers such as hyaluronic acid (HA) or hydroxypropyl methylcellulose (HPMC), may enhance corneal reepithelialization and wound healing [7-9]. The data of the current study supports the concept that this holds also true for C-NAC. The underlying mechanism is not entirely clear but may be at least partially related to the effects of unmodified chitosan on wound healing [17, 18]. It has been shown in previous studies that in a rabbit alkali burn model, chitosan reduces scar formation and increases the collagen density in the conjunctiva [19]. Further evidence shows that chitosan leads to an increased growth and proliferation of cultured corneal epithelial cells in vitro [20]. This effect has been mainly attributed to increased epithelial proliferation and migration induced via the extracellular signal-regulated kinase (ERK) pathway [21]. This may well be the mechanism that underlies increased corneal wound healing of C-NAC used in the study, although this hypothesis requires further investigation.

In addition, the specific chemical and biological properties of C-NAC may contribute to the observed beneficial effect on corneal wound healing. Chemically spoken, C-NAC is a positively charged macromolecule with chitosan as a polycationic polysaccharide backbone. Chitosan is further modified by the introduction of *N*-acetylcysteine (NAC) via nucleophilic substitution and by the introduction of thiol groups. The latter modification determines to a large degree the biological properties of C-NAC on the ocular surface [22]. Via the introduced thiol groups, C-NAC binds electrostatically and chemically to negatively charged reactive mucins of the ocular surface, thereby producing a stable glycocalyx-like structure. These scaffolding properties of C-NAC may lead to an enhanced stability of the polymer-

mucin network, resulting in a prolonged residence time [23, 24] and promoting corneal wound healing.

Prolonged ocular residence time of C-NAC in comparison to nonmodified chitosan was actually demonstrated in preclinical studies in a rabbit in vivo model using microPET technology [10]. The results show that C-NAC can be detected on the ocular surface for up to 48 hours [25] after application, an effect considerably longer than with unmodified chitosan.

The use of two independent methods for the assessment of corneal wound healing strengthens the data obtained in the present study. Classically, the measurement of lesion size is performed using fluorescein staining of the corneal defect followed by the measurement of wound size by means of slit lamp examination or photography [26–29]. This approach is however limited by the need for a dye to perform corneal staining, which in turn may influence wound healing. Further, the measurement of wound size itself is challenging, because it is dependent on complex optical properties such as the distance to the measured eye, refractive error of the examiner, and the magnification of the imaging device. To compensate for these limitations, we graded the corneal defect size based on calibrated photographical images of the ocular surface.

As a more sophisticated technique to measure epithelial defect size, a custom built ultra-high-resolution OCT system was used. The technical details of this device have been described in detail previously [14]. We have used this system in several human studies to assess precorneal tear film thickness [14, 30–32] as well as to measure corneal wound healing in humans (Bata et al. 2016 JAMA Ophthalmology, in press). The latter study shows that in humans, there is a good correlation between corneal wound size measured with OCT and measurements based on corneal fluorescein staining [17].

This finding is in agreement with the results of the current experiment (Figure 2). However, it was noted that the erosion area determined via OCT measurement was slightly smaller than the wound area determined from fluorescein images. This might be related to the different methods used for detection of the borders of the corneal defect. Thus, OCT detects the structural border of the epithelial wound based on differences in reflectivity of the different tissues. Fluorescein images, on the other hand, rely on an "indirect" visualization of the erosion boundary by detection of fluorescence light arising from new epithelial foci. This signal however is influenced by different factors, such as ambient light, amount of stimulation light, and dynamic range of the camera in use; slight variations of these parameters might lead to an overestimation of the real erosion size.

Our study also had some limitations that are worth to be mentioned. As topically applied agents may influence corneal wound healing per se, no generally accepted placebo control exists for studies on ocular surface disease. In the present study, PBS eye drops have been used twice daily to guarantee investigator masked conditions during the study. It can, however, not be excluded that PBS had a beneficial effect on corneal wound healing due to its lubrication effects leading to an underestimation of the effect of C-NAC. Further, it is not entirely clear to what extent data gained

Journal of Ophthalmology 5

in rabbit experiments reflect the situation of corneal wound healing in humans. However, because of their considerable advantages in comparison to other animal models, rabbit models of corneal healing have been widely used in the past to assess reepithelialization and scarring. It has been shown that the rabbit cornea responds to a large degree comparable to the human cornea in respect to wound healing time, the extent of scarring, and myofibroblast formation [33, 34]. In addition, the rabbit cornea is similar in size to the human cornea, which confirms its suitability of the model for translational research. [33].

In conclusion, our data show that C-NAC containing eye drops improve corneal wound healing in a rabbit model of corneal epithelial debridement and may therefore also be considered beneficial for the treatment of human corneal epithelial defects. In addition, we have demonstrated that ultrahigh-resolution OCT is an excellent, noninvasive, dye-free technique for the monitoring of corneal epithelial healing in both humans and experimental animals.

#### **Disclosure**

The funding organizations had no role in the design or conduct of this research.

#### **Conflicts of Interest**

Christine Hohenadl and Martin Prinz are employees of Croma Pharma, Leobendorf, Austria.

## Acknowledgments

All animal experiments were performed at the Department of Biomedical Research, Medical University of Vienna, Austria. This research was funded by the Austrian Federal Ministry of Economy, Family and Youth and the National Foundation of Research, Technology and Development.

## References

- [1] C. Y. Liu and W. W. Kao, "Corneal epithelial wound healing," *Progress in Molecular Biology and Translational Science*, vol. 134, pp. 61–71, 2015.
- [2] A. V. Ljubimov and M. Saghizadeh, "Progress in corneal wound healing," *Progress in Retinal and eye Research*, vol. 49, pp. 17–45, 2015.
- [3] T. Lin and L. Gong, "Sodium hyaluronate eye drops treatment for superficial corneal abrasion caused by mechanical damage: a randomized clinical trial in the People's Republic of China," *Drug Design, Development and Therapy*, vol. 9, pp. 687–694, 2015, Epub 2015/02/14.
- [4] A. J. Bron, P. Argüeso, M. Irkec, and F. V. Bright, "Clinical staining of the ocular surface: mechanisms and interpretations," *Progress in Retinal and eye Research*, vol. 44, pp. 36–61, 2015.
- [5] J. L. Wipperman and J. N. Dorsch, "Evaluation and management of corneal abrasions," *American Family Physician*, vol. 87, no. 2, pp. 114–120, 2013, Epub 2013/01/16.
- [6] K. L. Segal, P. M. Fleischut, C. Kim et al., "Evaluation and treatment of perioperative corneal abrasions," *Journal*

- of Ophthalmology, vol. 2014, Article ID 901901, 5 pages, 2014, Epub 2014/03/29.
- [7] G. M. Tosi, D. Marigliani, T. Bacci, A. Balestrazzi, G. Martone, and M. S. Polito, "Impact of intraoperative topical hydroxy-propyl methylcellulose 2% versus sodium hyaluronate 1.2% on corneal reepithelialization after intentional epithelial debridement during vitrectomy," *Cornea*, vol. 33, no. 9, pp. 942–945, 2014.
- [8] R. Pinheiro, C. Panfil, N. Schrage, and R. M. Dutescu, "Comparison of the lubricant eyedrops Optive(R), Vismed multi(R), and Cationorm(R) on the corneal healing process in an ex vivo model," *European Journal of Ophthalmology*, vol. 25, no. 5, pp. 379–384, 2015.
- [9] W. T. Ho, T. H. Chiang, S. W. Chang, Y. H. Chen, F. R. Hu, and I. J. Wang, "Enhanced corneal wound healing with hyaluronic acid and high-potassium artificial tears," *Clinical & Experimental Optometry: Journal of the Australian Optometrical Association.*, vol. 96, no. 6, pp. 536–541, 2013.
- [10] D. Dangl, M. Hornof, M. Hoffer, C. Kuntner, T. Wanek, and H. Kvaternik, "In vivo evaluation of ocular residence time of 124I-labelled thiolated chitosan in rabbits using microPET technology," *Investigative Ophthalmology & Visual Science*, vol. 50, no. 13, p. 3689, 2009.
- [11] F. Felice, Y. Zambito, E. Belardinelli, A. Fabiano, T. Santoni, and R. Di Stefano, "Effect of different chitosan derivatives on in vitro scratch wound assay: a comparative study," *International Journal of Biological Macromolecules*, vol. 76, pp. 236–241, 2015.
- [12] H. Zhang, A. Qadeer, and W. Chen, "In situ gelable interpenetrating double network hydrogel formulated from binary components: thiolated chitosan and oxidized dextran," *Bioma*cromolecules, vol. 12, no. 5, pp. 1428–1437, 2011.
- [13] D. Schmidl, R. Werkmeister, S. Kaya et al., "A controlled, randomized double-blind study to evaluate the safety and efficacy of chitosan-N-acetylcysteine for the treatment of dry eye syndrome," *Journal of Ocular Pharmacology and Therapeutics*, 2017.
- [14] R. M. Werkmeister, A. Alex, S. Kaya et al., "Measurement of tear film thickness using ultrahigh-resolution optical coherence tomography," *Investigative Ophthalmology & Visual Science*, vol. 54, no. 8, pp. 5578–5583, 2013.
- [15] American National Standards Institute, American National Standard for Safe Use of Lasers, The Laser Institute of America, Orlando, Fl, 2000, ANSI Z136.1-2000.
- [16] International Electrotechnical Commission, International Electrotechnical Commission IEC 60825-1, Safety of Laser Products Part 1: Equipment Classification and Requirements (IEC 60825-1:2007), 2007.
- [17] A. M. Bata, K. J. Witkowska, P. A. Wozniak et al., "Effect of a matrix therapy agent on corneal epithelial healing after standard collagen cross-linking in patients with keratoconus: a randomized clinical trial," *JAMA Ophthalmology*, vol. 134, 2016.
- [18] J. F. Rouland, C. E. Traverso, I. Stalmans et al., "Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma," *The British Journal of Ophthalmology*, vol. 97, no. 2, pp. 196–200, 2013.
- [19] H. Yang, Y. Xiang, and X. N. Zhang, "Experimental study on the effects of chitosan on the conjunctiva scar formation and symblepharon," *Zhonghua Yan Ke Za Zhi*, vol. 42, no. 4, pp. 313–317, 2006.

- [20] L. K. Yeh, Y. H. Chen, C. S. Chiu, F. R. Hu, T. H. Young, and I. J. Wang, "The phenotype of bovine corneal epithelial cells on chitosan membrane," *Journal of Biomedical Materials Research. Part a*, vol. 90, no. 1, pp. 18–26, 2009.
- [21] R. Cui, Q. Lu, Y. Teng, K. Li, and N. Li, "Chitosan promoted the corneal epithelial wound healing via activation of ERK pathway," *Current eye Research*, vol. 42, pp. 21–27, 2016.
- [22] S. Bonengel and A. Bernkop-Schnurch, "Thiomers—from bench to market," Journal of Controlled Release: Official Journal of the Controlled Release Society., vol. 195, pp. 120– 129, 2014.
- [23] T. Hongyok, J. J. Chae, Y. J. Shin, D. Na, L. Li, and R. S. Chuck, "Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye," *Archives of Ophthalmology*, vol. 127, no. 4, pp. 525–532, 2009.
- [24] M. D. Hornof, C. E. Kast, and A. Bernkop-Schnurch, "In vitro evaluation of the viscoelastic properties of chitosanthioglycolic acid conjugates," European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV., vol. 55, no. 2, pp. 185–190, 2003.
- [25] A. Partenhauser and A. Bernkop-Schnurch, "Mucoadhesive polymers in the treatment of dry X syndrome," *Drug Discovery Today*, vol. 21, no. 7, pp. 1051–1062, 2016.
- [26] I. M. Aslanides, V. D. Selimis, N. V. Bessis, and P. N. Georgoudis, "A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)," Clinical Ophthalmology (Auckland, NZ), vol. 9, pp. 685–690, 2015.
- [27] J. H. Chung, "Correlation between epithelial healing rate and initial wound size in contact lens-induced central epithelial abrasion," *Ophthalmologica*, vol. 212, no. 1, pp. 46–49, 1998, Epub 1998/01/23.
- [28] G. D. Kymionis, D. A. Liakopoulos, M. A. Grentzelos et al., "Effect of the regenerative agent poly(carboxymethylglucose sulfate) on corneal wound healing after corneal cross-linking for keratoconus," *Cornea*, vol. 34, no. 8, pp. 928–931, 2015, Epub 2015/06/10.
- [29] M. Menghini, P. B. Knecht, C. Kaufmann et al., "Treatment of traumatic corneal abrasions: a three-arm, prospective, randomized study," *Ophthalmic Research*, vol. 50, no. 1, pp. 13–18, 2013, Epub 2013/05/09.
- [30] S. Kaya, D. Schmidl, L. Schmetterer et al., "Effect of hyaluronic acid on tear film thickness as assessed with ultra-high resolution optical coherence tomography," *Acta Ophthalmologica*, vol. 93, no. 5, pp. 439–443, 2015.
- [31] D. Schmidl, K. J. Witkowska, S. Kaya et al., "The association between subjective and objective parameters for the assessment of dry-eye syndrome," *Investigative Ophthalmology & Visual Science*, vol. 56, no. 3, pp. 1467–1472, 2015.
- [32] D. Schmidl, L. Schmetterer, K. J. Witkowska et al., "Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease," *Cornea*, vol. 34, no. 4, pp. 421–426, 2015.
- [33] M. A. Stepp, J. D. Zieske, V. Trinkaus-Randall et al., "Wounding the cornea to learn how it heals," *Experimental eye Research*, vol. 121, pp. 178–193, 2014.
- [34] J. Imanishi, K. Kamiyama, I. Iguchi, M. Kita, C. Sotozono, and S. Kinoshita, "Growth factors: importance in wound healing and maintenance of transparency of the cornea," *Progress in Retinal and eye Research*, vol. 19, no. 1, pp. 113–129, 2000.